Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab. [electronic resource]
Producer: 20110922Description: 506-13 p. digitalISSN:- 1943-4723
- Adult
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors -- therapeutic use
- Antibodies, Monoclonal -- therapeutic use
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Bevacizumab
- Biomarkers -- blood
- Bone Density Conservation Agents -- therapeutic use
- Bone Neoplasms -- drug therapy
- Breast Neoplasms -- pathology
- Carcinoma, Non-Small-Cell Lung -- pathology
- Collagen Type I -- blood
- Dental Care
- Diphosphonates -- therapeutic use
- Female
- Follow-Up Studies
- Humans
- Imidazoles -- therapeutic use
- Jaw Diseases -- etiology
- Lung Neoplasms -- pathology
- Male
- Middle Aged
- Osteonecrosis -- etiology
- Peptides -- blood
- Periodontal Diseases -- therapy
- Radiography, Panoramic
- Risk Factors
- Tooth Extraction
- Zoledronic Acid
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.